Barinthus Biotherapeutics plc. (BRNS)

Every figure below is the company's own, as filed. Nothing is estimated and nothing is smoothed — a period the filing does not support is left blank rather than drawn. Quarters are the company's own, counted from its financial year ending 12-31. Amounts in USD.

Revenue TTM

0 20M 40M 60M Q4 '20: 4.8M Q1 '21: 4.3M Q2 '21: 3.9M Q3 '21: 623K Q4 '21: 268K Q1 '22: 15.1M Q2 '22: 32.1M Q3 '22: 38.2M Q4 '22: 44.7M Q1 '23: 30.2M Q2 '23: 13.4M Q3 '23: 7.3M Q4 '23: 802K Q1 '24: 334K Q2 '24: 0 Q3 '24: 15M Q4 '24: 15M Q1 '21 Q4 '21 Q3 '22 Q2 '23 Q1 '24 Q4 '24

Gross Profit TTM

Nothing in this filer's XBRL supports this figure for the periods asked for, so there is nothing to draw. That is a gap in the filing, not a zero.

Operating Income TTM

-90M -60M -30M 0 30M 60M 90M Q4 '20: -20M Q1 '21: -21.6M Q2 '21: -34.1M Q3 '21: -38.2M Q4 '21: -45.2M Q1 '22: -38.4M Q2 '22: -8.3M Q3 '22: 4.5M Q4 '23: -83.9M Q1 '24: -79.3M Q2 '24: -71.3M Q3 '24: -64.6M Q4 '24: -68M Q1 '25: -71.7M Q2 '25: -76.7M Q3 '25: -82.4M Q4 '25: -70.6M Q1 '26: -56M Q2 '26: -43.7M Q4 '20 Q3 '21 Q2 '22 Q1 '24 Q4 '24 Q3 '25 Q2 '26

Net Income TTM

-90M -60M -30M 0 30M 60M 90M Q4 '20: -17.7M Q1 '21: -29.2M Q2 '21: -41.5M Q3 '21: -46.2M Q4 '21: -50.9M Q1 '22: -33M Q2 '22: -1.4M Q3 '22: 11.4M Q4 '23: -73.3M Q1 '24: -70.7M Q2 '24: -63.8M Q3 '24: -57.8M Q4 '24: -61.1M Q1 '25: -65.2M Q2 '25: -69.4M Q3 '25: -75.9M Q4 '25: -66.4M Q1 '26: -52.3M Q2 '26: -41.8M Q4 '20 Q3 '21 Q2 '22 Q1 '24 Q4 '24 Q3 '25 Q2 '26

Cost of Revenue TTM

Nothing in this filer's XBRL supports this figure for the periods asked for, so there is nothing to draw. That is a gap in the filing, not a zero.

Operating Cash Flow TTM

-75M -50M -25M 0 25M 50M 75M Q4 '20: -11M Q1 '21: -14.7M Q2 '21: -28.4M Q3 '21: -29.5M Q4 '21: -32.6M Q1 '22: -31.2M Q2 '22: -25M Q3 '22: -11.1M Q4 '22: -14.4M Q1 '23: -11M Q2 '23: -19.6M Q3 '23: -42.7M Q4 '23: -50.9M Q1 '24: -59.6M Q2 '24: -54.6M Q3 '24: -61.6M Q4 '24: -28.9M Q1 '25: -32M Q2 '25: -38.1M Q3 '25: -30.7M Q4 '25: -48M Q1 '26: -36.4M Q2 '26: -26.4M Q1 '21 Q4 '21 Q3 '22 Q2 '23 Q1 '24 Q4 '24 Q3 '25 Q2 '26

Free Cash Flow TTM

-75M -50M -25M 0 25M 50M 75M Q4 '20: -11.3M Q1 '21: -15.3M Q2 '21: -29.2M Q3 '21: -30.4M Q4 '21: -33.7M Q1 '22: -33M Q2 '22: -28.7M Q3 '22: -17M Q4 '22: -20.6M Q1 '23: -18.6M Q2 '23: -28.1M Q3 '23: -48.8M Q4 '23: -56.3M Q1 '24: -62.8M Q2 '24: -55M Q3 '24: -62.1M Q4 '24: -29.8M Q1 '25: -32.6M Q2 '25: -38.6M Q3 '25: -31M Q4 '25: -48M Q1 '26: -36.5M Q2 '26: -26.4M Q1 '21 Q4 '21 Q3 '22 Q2 '23 Q1 '24 Q4 '24 Q3 '25 Q2 '26

Operating cash flow minus capital expenditure.

Shares Outstanding Quarterly

0 15M 30M 45M Q3 '20: 15.9M Q1 '21: 8.1M Q2 '21: 24.9M Q3 '21: 34.8M Q1 '22: 38.3M Q2 '22: 38.2M Q3 '22: 38.2M Q1 '23: 38M Q2 '23: 38.4M Q3 '23: 38.5M Q1 '24: 38.8M Q2 '24: 39M Q3 '24: 39.4M Q1 '25: 40.3M Q2 '25: 40.3M Q3 '25: 40.7M Q1 '26: 40.8M Q2 '26: 40.8M Q2 '21 Q2 '22 Q2 '23 Q2 '24 Q2 '25 Q2 '26

Weighted average diluted, as the filer reports it for each period. An average cannot be added across periods, so this one is always shown per period the filer tagged rather than as a trailing year.

EPS TTM

-4.50 -3.00 -1.50 0.00 1.50 3.00 4.50 Q4 '20: -2.25 Q1 '21: -3.66 Q2 '21: -3.85 Q3 '21: -3.99 Q4 '21: -3.05 Q1 '22: -1.08 Q2 '22: -0.03 Q3 '22: 0.32 Q4 '23: -1.92 Q1 '24: -1.84 Q2 '24: -1.65 Q3 '24: -1.49 Q4 '24: -1.55 Q1 '25: -1.64 Q2 '25: -1.73 Q3 '25: -1.88 Q4 '25: -1.64 Q1 '26: -1.29 Q2 '26: -1.03 Q4 '20 Q3 '21 Q2 '22 Q1 '24 Q4 '24 Q3 '25 Q2 '26

The filer's own published earnings a share for each quarter, four quarters added up. The company page divides trailing net income by the share count instead, which lands within about 1% of this and is not the same sum, so the two are named differently rather than presented as one figure.